Giorgos D. Michalopoulos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Giorgos D. Michalopoulos has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Mohamad Bydon
Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA
10 shared publications Sally El Sammak
Neuro-Informatics Laboratory, Mayo Clinic, Rochester, USA
5 shared publicationsRyan Jarrah
Neuro-Informatics Laboratory, Mayo Clinic, Rochester, USA
3 shared publications- Allan Burton Dietz
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
2 shared publications Anthony J. Windebank
Department of Neurology, Mayo Clinic, Rochester, USA
2 shared publications- Anthony Loren Mikula
Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA
2 shared publications
Latest Publications
- 23 June 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 46 (12) , 2610-2616
Pituitary Photon-Counting Detector CT for Cushing Disease: Preoperative Lesion Localization, Intraoperative Findings, and Postoperative Outcomes
MRI fails to localize a tumor in up to 40% of cases of ACTH dependent Cushing Disease (CD), impacting patient outcomes and creating uncertainty in the diagnosis. Photon-counting detector CT (PCD-CT) is a new CT technology with better imaging performance than conventional CT. PCD-CT is a novel imaging technique for CD, especially for MR-negative cases, however its application to CD remains unknown. We present a cohort of consecutive patients with a pre-operative PCD-CT undergoing transsphenoidal surgery for CD at a single institution from September 2023 to January 2025. All patients underwent gadolinium-enhanced pituitary MRI for baseline work-up and PCD-CT as part of their preoperative planning imaging. Both imaging modalities were used to localize the lesion and guide surgical planning. The accuracies of MRI and PCD-CT were based on confirmation of the lesion location by a combination of intraoperative visualization, pathologic confirmation, and postoperative biochemical remission, and were compared with each other via Fisher's exact test. Twenty-five patients with CD were included in this analysis. The cohort's median age was 50 years old, and 88% were female. At diagnosis, 88% had central obesity, 76% had hypertension, 48% had type II diabetes mellitus, and 20% had osteoporosis. Contrast-enhanced MRI accurately identified 56% of lesions, while it was negative in 24% and misleading in 20%. Dynamic contrast-enhanced PCD-CT was superior in localizing CD (p=0.01), accurately identifying 92% of lesions, while it was negative in 4% and misleading in 4% of cases. Early postoperative biochemical remission was achieved in 88% of cases, while 84% remained in remission at follow-up. PCD-CT had a high rate of adenoma localization confirmed intraoperatively, even among MR-negative cases, potentially leading to high remission and gland preservation rates. Its role in the clinical workflow of preoperative evaluation for CD requires further investigation, but current evidence supports its value in lesion localization, especially in MR-negative disease. CD= cushing disease; PCD= photon counting detector.
- 23 June 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 46 (12) , 2610-2616
Pituitary Photon-Counting Detector CT for Cushing Disease: Preoperative Lesion Localization, Intraoperative Findings, and Postoperative Outcomes
MRI fails to localize a tumor in up to 40% of cases of ACTH dependent Cushing Disease (CD), impacting patient outcomes and creating uncertainty in the diagnosis. Photon-counting detector CT (PCD-CT) is a new CT technology with better imaging performance than conventional CT. PCD-CT is a novel imaging technique for CD, especially for MR-negative cases, however its application to CD remains unknown. We present a cohort of consecutive patients with a pre-operative PCD-CT undergoing transsphenoidal surgery for CD at a single institution from September 2023 to January 2025. All patients underwent gadolinium-enhanced pituitary MRI for baseline work-up and PCD-CT as part of their preoperative planning imaging. Both imaging modalities were used to localize the lesion and guide surgical planning. The accuracies of MRI and PCD-CT were based on confirmation of the lesion location by a combination of intraoperative visualization, pathologic confirmation, and postoperative biochemical remission, and were compared with each other via Fisher's exact test. Twenty-five patients with CD were included in this analysis. The cohort's median age was 50 years old, and 88% were female. At diagnosis, 88% had central obesity, 76% had hypertension, 48% had type II diabetes mellitus, and 20% had osteoporosis. Contrast-enhanced MRI accurately identified 56% of lesions, while it was negative in 24% and misleading in 20%. Dynamic contrast-enhanced PCD-CT was superior in localizing CD (p=0.01), accurately identifying 92% of lesions, while it was negative in 4% and misleading in 4% of cases. Early postoperative biochemical remission was achieved in 88% of cases, while 84% remained in remission at follow-up. PCD-CT had a high rate of adenoma localization confirmed intraoperatively, even among MR-negative cases, potentially leading to high remission and gland preservation rates. Its role in the clinical workflow of preoperative evaluation for CD requires further investigation, but current evidence supports its value in lesion localization, especially in MR-negative disease. CD= cushing disease; PCD= photon counting detector.
- 1 October 2024
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 28 (6) , 893-894
Ventral Thoracic Cerebrospinal Fluid Leak Repair in Spontaneous Intracranial Hypotension Complicated by Superficial Siderosis: 2-Dimensional Operative Video
- 1 October 2024
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 28 (6) , 893-894
Ventral Thoracic Cerebrospinal Fluid Leak Repair in Spontaneous Intracranial Hypotension Complicated by Superficial Siderosis: 2-Dimensional Operative Video
- Open Access
- 1 August 2024
- Published by SAGE Publications in Global Spine Journal
- Vol. 15 (4) , 1914-1923
Paraspinal Sarcopenia and Lower Hounsfield Units are Independent Predictors of Increased Risk for Proximal Junctional Complications Following Thoracolumbar Fusions Terminating in the Upper Thoracic Spine
Study Design: Retrospective cohort study. Objective: The impact of paraspinal sarcopenia following fusions that extend to the upper thoracic spine remain unknown. The purpose of the present study was to assess the impact of sarcopenia on the development of PJK and PJF following spine fusion surgery from the upper thoracic spine to the pelvis. Methods: We performed a retrospective review of patients who underwent spine fusion surgery that extended caudally to the pelvis and terminated cranially between T1-6. The cohort was divided into 2 groups: (1) patients without PJK or PJF and (2) patients with PJK and/or PJF. Univariate and multivariate analyses were performed to determine risk factors for the development of proximal junctional complications. Results: We identified 81 patients for inclusion in this study. Mean HU at the UIV was 186.1 ± 47.5 in the cohort of patients without PJK or PJF, which was substantially higher than values recorded in the PJK/PJF subgroup (142.4 ± 40.2) ( P < 0.001). Severe multifidus sarcopenia was identified at a higher rate in the subgroup of patients who developed proximal junction pathology (66.7%) than in the subgroup of patients who developed neither PJK nor PJF (7.4%; P < 0.001). Multivariate analysis demonstrated both low HU at the UIV and moderate-severe multifidus sarcopenia to be risk factors for the development of PJK and PJF. Conclusions: Severe paraspinal sarcopenia and diminished bone density at the UIV impart an increased risk of developing PJK and PJF in following thoracolumbar fusions from the upper thoracic spine to the pelvis.
- 1 August 2024
- Published by SAGE Publications in Global Spine Journal
- Vol. 15 (4) , 1914-1923
Open AccessParaspinal Sarcopenia and Lower Hounsfield Units are Independent Predictors of Increased Risk for Proximal Junctional Complications Following Thoracolumbar Fusions Terminating in the Upper Thoracic Spine
Study Design: Retrospective cohort study. Objective: The impact of paraspinal sarcopenia following fusions that extend to the upper thoracic spine remain unknown. The purpose of the present study was to assess the impact of sarcopenia on the development of PJK and PJF following spine fusion surgery from the upper thoracic spine to the pelvis. Methods: We performed a retrospective review of patients who underwent spine fusion surgery that extended caudally to the pelvis and terminated cranially between T1-6. The cohort was divided into 2 groups: (1) patients without PJK or PJF and (2) patients with PJK and/or PJF. Univariate and multivariate analyses were performed to determine risk factors for the development of proximal junctional complications. Results: We identified 81 patients for inclusion in this study. Mean HU at the UIV was 186.1 ± 47.5 in the cohort of patients without PJK or PJF, which was substantially higher than values recorded in the PJK/PJF subgroup (142.4 ± 40.2) ( P < 0.001). Severe multifidus sarcopenia was identified at a higher rate in the subgroup of patients who developed proximal junction pathology (66.7%) than in the subgroup of patients who developed neither PJK nor PJF (7.4%; P < 0.001). Multivariate analysis demonstrated both low HU at the UIV and moderate-severe multifidus sarcopenia to be risk factors for the development of PJK and PJF. Conclusions: Severe paraspinal sarcopenia and diminished bone density at the UIV impart an increased risk of developing PJK and PJF in following thoracolumbar fusions from the upper thoracic spine to the pelvis.
- Open Access
- 5 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-3
Author Correction: Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial
- 5 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-3
Open AccessAuthor Correction: Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial
- Top Cited PapersOpen Access
- 1 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial
: Intrathecal delivery of autologous culture-expanded adipose tissue-derived mesenchymal stem cells (AD-MSC) could be utilized to treat traumatic spinal cord injury (SCI). This Phase I trial (ClinicalTrials.gov: NCT03308565) included 10 patients with American Spinal Injury Association Impairment Scale (AIS) grade A or B at the time of injury. The study’s primary outcome was the safety profile, as captured by the nature and frequency of adverse events. Secondary outcomes included changes in sensory and motor scores, imaging, cerebrospinal fluid markers, and somatosensory evoked potentials. The manufacturing and delivery of the regimen were successful for all patients. The most commonly reported adverse events were headache and musculoskeletal pain, observed in 8 patients. No serious AEs were observed. At final follow-up, seven patients demonstrated improvement in AIS grade from the time of injection. In conclusion, the study met the primary endpoint, demonstrating that AD-MSC harvesting and administration were well-tolerated in patients with traumatic SCI.
- 1 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Top Cited PapersOpen AccessIntrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial
: Intrathecal delivery of autologous culture-expanded adipose tissue-derived mesenchymal stem cells (AD-MSC) could be utilized to treat traumatic spinal cord injury (SCI). This Phase I trial (ClinicalTrials.gov: NCT03308565) included 10 patients with American Spinal Injury Association Impairment Scale (AIS) grade A or B at the time of injury. The study’s primary outcome was the safety profile, as captured by the nature and frequency of adverse events. Secondary outcomes included changes in sensory and motor scores, imaging, cerebrospinal fluid markers, and somatosensory evoked potentials. The manufacturing and delivery of the regimen were successful for all patients. The most commonly reported adverse events were headache and musculoskeletal pain, observed in 8 patients. No serious AEs were observed. At final follow-up, seven patients demonstrated improvement in AIS grade from the time of injection. In conclusion, the study met the primary endpoint, demonstrating that AD-MSC harvesting and administration were well-tolerated in patients with traumatic SCI.
- 21 August 2023
- Published by Elsevier in World Neurosurgery
- Vol. 179, e222-e231
Prediction Model for Neurogenic Bladder Recovery One Year After Traumatic Spinal Cord Injury
- 21 August 2023
- Published by Elsevier in World Neurosurgery
- Vol. 179, e222-e231
Prediction Model for Neurogenic Bladder Recovery One Year After Traumatic Spinal Cord Injury
- 6 January 2023
- Published by Elsevier in World Neurosurgery
- Vol. 172, e278-e290
Surgical Management of Hirayama Disease (Monomelic Amyotrophy): Systematic Review and Meta-Analysis of Patient-Level Data
- 6 January 2023
- Published by Elsevier in World Neurosurgery
- Vol. 172, e278-e290
Surgical Management of Hirayama Disease (Monomelic Amyotrophy): Systematic Review and Meta-Analysis of Patient-Level Data
- 26 November 2022
- Published by Elsevier in World Neurosurgery
- Vol. 170, e700-e711
Risk Factors for Allograft Subsidence Following Anterior Cervical Discectomy and Fusion
- 26 November 2022
- Published by Elsevier in World Neurosurgery
- Vol. 170, e700-e711
Risk Factors for Allograft Subsidence Following Anterior Cervical Discectomy and Fusion
- 25 October 2022
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 92 (2) , 308-316
Trends in Reimbursement and Approach Selection for Lumbar Arthrodesis
BACKGROUND: Changes in reimbursement policies have been demonstrated to correlate with clinical practice. OBJECTIVE: To investigate trends in physician reimbursement for anterior, posterior, and combined anterior/posterior (AP) lumbar arthrodesis and relative utilization of AP. METHODS: We queried the American College of Surgeons National Surgical Quality Improvement Project registry for anterior, posterior, and AP lumbar arthrodeses during 2010 and 2020. Work relative value units per operative hour (wRVUs/h) were calculated for each procedure. Trends in reimbursement and utilization of the AP approach were assessed with linear regression. Subgroup analyses of age and underlying pathology of AP arthrodesis were also performed. RESULTS: During 2010 and 2020, AP arthrodesis was associated with significantly higher average wRVUs/h compared with anterior and posterior arthrodesis (AP = 17.4, anterior = 12.4, posterior = 14.5). The AP approach had a significant yearly increase in wRVUs/h (coefficient = 0.48, P = .042), contrary to anterior (coefficient = −0.01, P = .308) and posterior (coefficient = −0.13, P = .006) approaches. Utilization of AP approaches over all arthrodeses increased from 7.5% in 2010 to 15.3% in 2020 (yearly average increase 0.79%, P < .001). AP fusions increased significantly among both degenerative and deformity cases (coefficients 0.88 and 1.43, respectively). The mean age of patients undergoing AP arthrodesis increased by almost 10 years from 2010 to 2020. Rates of major 30-day complications were 2.7%, 3.1%, and 3.5% for AP, anterior, and posterior arthrodesis, respectively. CONCLUSION: AP lumbar arthrodesis was associated with higher and increasing reimbursement (wRVUs/h) during the period 2010 to 2020. Reimbursement for anterior arthrodesis was relatively stable, while reimbursement for posterior arthrodesis decreased. The utilization of the combined AP approach relative to the other approaches increased significantly during the period of interest.
- 25 October 2022
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 92 (2) , 308-316
Trends in Reimbursement and Approach Selection for Lumbar Arthrodesis
BACKGROUND: Changes in reimbursement policies have been demonstrated to correlate with clinical practice. OBJECTIVE: To investigate trends in physician reimbursement for anterior, posterior, and combined anterior/posterior (AP) lumbar arthrodesis and relative utilization of AP. METHODS: We queried the American College of Surgeons National Surgical Quality Improvement Project registry for anterior, posterior, and AP lumbar arthrodeses during 2010 and 2020. Work relative value units per operative hour (wRVUs/h) were calculated for each procedure. Trends in reimbursement and utilization of the AP approach were assessed with linear regression. Subgroup analyses of age and underlying pathology of AP arthrodesis were also performed. RESULTS: During 2010 and 2020, AP arthrodesis was associated with significantly higher average wRVUs/h compared with anterior and posterior arthrodesis (AP = 17.4, anterior = 12.4, posterior = 14.5). The AP approach had a significant yearly increase in wRVUs/h (coefficient = 0.48, P = .042), contrary to anterior (coefficient = −0.01, P = .308) and posterior (coefficient = −0.13, P = .006) approaches. Utilization of AP approaches over all arthrodeses increased from 7.5% in 2010 to 15.3% in 2020 (yearly average increase 0.79%, P < .001). AP fusions increased significantly among both degenerative and deformity cases (coefficients 0.88 and 1.43, respectively). The mean age of patients undergoing AP arthrodesis increased by almost 10 years from 2010 to 2020. Rates of major 30-day complications were 2.7%, 3.1%, and 3.5% for AP, anterior, and posterior arthrodesis, respectively. CONCLUSION: AP lumbar arthrodesis was associated with higher and increasing reimbursement (wRVUs/h) during the period 2010 to 2020. Reimbursement for anterior arthrodesis was relatively stable, while reimbursement for posterior arthrodesis decreased. The utilization of the combined AP approach relative to the other approaches increased significantly during the period of interest.
- Open Access
- 1 May 2022
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Spine
- Vol. 36 (5) , 753-766
Minimally invasive versus open lumbar spinal fusion: a matched study investigating patient-reported and surgical outcomes
OBJECTIVE: With the expanding indications for and increasing popularity of minimally invasive surgery (MIS) for lumbar spinal fusion, large-scale outcomes analysis to compare MIS approaches with open procedures is warranted. METHODS: The authors queried the Quality Outcomes Database for patients who underwent elective lumbar fusion for degenerative spine disease. They performed optimal matching, at a 1:2 ratio between patients who underwent MIS and those who underwent open lumbar fusion, to create two highly homogeneous groups in terms of 33 baseline variables (including demographic characteristics, comorbidities, symptoms, patient-reported scores, indications, and operative details). The outcomes of interest were overall satisfaction, decrease in Oswestry Disability Index (ODI), and back and leg pain, as well as hospital length of stay (LOS), operative time, reoperations, and incidental durotomy rate. Satisfaction was defined as a score of 1 or 2 on the North American Spine Society scale. Minimal clinically important difference (MCID) in ODI was defined as ≥ 30% decrease from baseline. Outcomes were assessed at the 3- and 12-month follow-up evaluations. RESULTS: After the groups were matched, the MIS and open groups consisted of 1483 and 2966 patients, respectively. Patients who underwent MIS fusion had higher odds of satisfaction at 3 months (OR 1.4, p = 0.004); no difference was demonstrated at 12 months (OR 1.04, p = 0.67). Lumbar stenosis, single-level fusion, higher American Society of Anesthesiologists Physical Status Classification System grade, and absence of spondylolisthesis were most prominently associated with higher odds of satisfaction with MIS compared with open surgery. Patients in the MIS group had slightly lower ODI scores at 3 months (mean difference 1.61, p = 0.006; MCID OR 1.14, p = 0.0495) and 12 months (mean difference 2.35, p < 0.001; MCID OR 1.29, p < 0.001). MIS was also associated with a greater decrease in leg and back pain at both follow-up time points. The two groups did not differ in operative time and incidental durotomy rate; however, LOS was shorter for the MIS group. Revision surgery at 12 months was less likely for patients who underwent MIS (4.1% vs 5.6%, p = 0.032). CONCLUSIONS: In patients who underwent lumbar fusion for degenerative spinal disease, MIS was associated with higher odds of satisfaction at 3 months postoperatively. No difference was demonstrated at the 12-month follow-up. MIS maintained a small, yet consistent, superiority in decreasing ODI and back and leg pain, and MIS was associated with a lower reoperation rate.
- 1 May 2022
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Spine
- Vol. 36 (5) , 753-766
Open AccessMinimally invasive versus open lumbar spinal fusion: a matched study investigating patient-reported and surgical outcomes
OBJECTIVE: With the expanding indications for and increasing popularity of minimally invasive surgery (MIS) for lumbar spinal fusion, large-scale outcomes analysis to compare MIS approaches with open procedures is warranted. METHODS: The authors queried the Quality Outcomes Database for patients who underwent elective lumbar fusion for degenerative spine disease. They performed optimal matching, at a 1:2 ratio between patients who underwent MIS and those who underwent open lumbar fusion, to create two highly homogeneous groups in terms of 33 baseline variables (including demographic characteristics, comorbidities, symptoms, patient-reported scores, indications, and operative details). The outcomes of interest were overall satisfaction, decrease in Oswestry Disability Index (ODI), and back and leg pain, as well as hospital length of stay (LOS), operative time, reoperations, and incidental durotomy rate. Satisfaction was defined as a score of 1 or 2 on the North American Spine Society scale. Minimal clinically important difference (MCID) in ODI was defined as ≥ 30% decrease from baseline. Outcomes were assessed at the 3- and 12-month follow-up evaluations. RESULTS: After the groups were matched, the MIS and open groups consisted of 1483 and 2966 patients, respectively. Patients who underwent MIS fusion had higher odds of satisfaction at 3 months (OR 1.4, p = 0.004); no difference was demonstrated at 12 months (OR 1.04, p = 0.67). Lumbar stenosis, single-level fusion, higher American Society of Anesthesiologists Physical Status Classification System grade, and absence of spondylolisthesis were most prominently associated with higher odds of satisfaction with MIS compared with open surgery. Patients in the MIS group had slightly lower ODI scores at 3 months (mean difference 1.61, p = 0.006; MCID OR 1.14, p = 0.0495) and 12 months (mean difference 2.35, p < 0.001; MCID OR 1.29, p < 0.001). MIS was also associated with a greater decrease in leg and back pain at both follow-up time points. The two groups did not differ in operative time and incidental durotomy rate; however, LOS was shorter for the MIS group. Revision surgery at 12 months was less likely for patients who underwent MIS (4.1% vs 5.6%, p = 0.032). CONCLUSIONS: In patients who underwent lumbar fusion for degenerative spinal disease, MIS was associated with higher odds of satisfaction at 3 months postoperatively. No difference was demonstrated at the 12-month follow-up. MIS maintained a small, yet consistent, superiority in decreasing ODI and back and leg pain, and MIS was associated with a lower reoperation rate.